Subcutaneous · GLP-1 agonist
Efpeglenatide
14 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
14
Active
2
Recruiting
1
Completed
6
Sites
461
Countries
31
Endpoints
94
Composite endpoints
14
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 1
2
Phase 2
4
Phase 2/3
1
Phase 3
7
Trials by status
Recruiting
1
Active, not recruiting
1
Completed
6
Terminated
4
Unknown
2
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Glycemic / diabetes
40
Weight & body composition
21
Safety / tolerability / PK
21
Cardiometabolic biomarkers
6
Cardiovascular outcomes
3
Renal / kidney
1
Patient-reported / QoL
1
Other (unclassified)
1
Most-measured metrics
Top 20 metrics across this asset's endpoints
HbA1c, changeGlycemic
11
Body weight, absolute change (kg)Weight
9
Documented hypoglycemiaSafety/PK
9
Fasting glucose, changeGlycemic
8
HbA1c <7.0% achievementGlycemic
7
Treatment-emergent AEs (any)Safety/PK
5
Waist circumference, changeWeight
3
Immunogenicity (ADA)Safety/PK
2
3-point MACECV
2
BMI, changeWeight
2
Body weight, % changeWeight
2
≥5% weight-loss respondersWeight
2
HbA1c <6.5% achievementGlycemic
1
AUC₀–∞Safety/PK
1
5-point MACECV
1
Custom renal compositeRenal
1
≥10% weight-loss respondersWeight
1
IWQOL-Lite physicalPRO/QoL
1
Plasma concentration (steady state)Safety/PK
1
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
14 of 14